NICE Recommends Two Diagnostics to Detect Endometriosis in England
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- The National Institute for Health and Care Excellence (NICE) has recommended Endosure and Endotest for routine use in England, marking a significant advancement in the diagnostic pathway for endometriosis within the National Health Service (NHS).
- These recommended diagnostics represent a move towards non-invasive methods for identifying endometriosis, aiming to reduce the current diagnostic delay which often exceeds several years and relies on invasive surgical procedures or symptom-based assessments.
- Endometriosis is a prevalent condition, affecting approximately 10% of women of reproductive age, highlighting the substantial clinical need for improved and earlier diagnostic capabilities.
- The NICE recommendation is expected to facilitate broader access to these new diagnostic tools for patients, funded by taxpayer resources, thereby potentially improving patient outcomes through earlier intervention.
- For the life sciences sector, this decision signifies a positive development in regulatory and reimbursement landscapes for diagnostics targeting women's health, an area historically underserved by research and clinical adoption.
The National Institute for Health and Care Excellence (NICE) has recommended Endosure and Endotest, two diagnostic tests for endometriosis, for routine use in England. The decision means that women in England will now have access to new, taxpayer-funded tests for the condition.
The recommendation applies to regular use within the National Health Service (NHS). Specific details on the tests’ performance, cost, or implementation timeline were not included in the announcement.
Context for the life sciences
Endometriosis affects an estimated one in ten women of reproductive age, yet diagnosis often takes years due to reliance on invasive surgery or symptom-based assessments. Non-invasive diagnostic tools like Endosure and Endotest represent a shift in how the condition can be identified earlier and more broadly. For biotech and medtech developers, the NICE recommendation signals a growing regulatory and reimbursement pathway for diagnostics targeting women’s health conditions that have historically received less research investment and slower clinical adoption.
Source: original report